
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
View the Pharmaceutical Executive September 2025 issue in an interactive format.
Click
about 1 year ago
Can AI Point the Way?about 1 year ago
Turning AI Pilots into Enterprise Valueabout 1 year ago
Paul Hudson: A Mindset for Miraclesabout 1 year ago
How AI is Shaping KOL and DOL Identificationabout 1 year ago
Beyond the Pitch: Tapping Synergies in Earned Media Engagementabout 1 year ago
What Innovation in PBM Management Really Looks Likeabout 1 year ago
Measuring the ROI of SPP Adherence Programs




